Clinical Trial Update: Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of the IL-6 receptor inhibitor sarilumab with ipilimumab, nivolumab, and relatlimab for unresectable stag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Unresectable Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• Sarilumab (sarilumab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Melanoma, Unresectable Melanoma | Phase 2 | Status: RECRUITING